This debut video episode of the In Vivo podcast examines the successes and pitfalls of the commercial launch of Yescarta (axicabtagene ciloleucel), Kite Pharma’s CAR-T therapy for relapsed/refractory large B-cell lymphoma. David Wild, senior reporter at In Vivo, is joined by Harris Kaplan, who consulted on the launch and conducted interviews with physicians, nurses, and hospital administrators before and after it, and is managing partner of Litmys, a life sciences commercial strategy consulting firm; Diane Parks, who led the Yescarta launch for Kite; and Jim Haag, a patient who received CAR-T therapy. It's a candid, unfiltered look at the gap between what innovation promises and what the healthcare system actually delivers.

Here are some of Harris Kaplan’s contributed articles for In Vivo:

Commercialization 3.0: Achieving New Product Success In Health Care’s New Era

Commercialization 3.0: Recognizing And Managing The Human Side Of Change

Physician Behavioral Inertia: Innovation’s Greatest Enemy